2022年9月1日-4日，全球肝癌领域学术盛典——第16届国际肝癌协会年会（ILCA2022）将在西班牙马德里召开！来自世界各地的肝癌专家共同集结在一起，重新开启线下关于肝癌基础与临床、研究和技术的学术碰撞！大会共收录了来自全球50多个国家、800多位学者的最新研究成果。本文特将本届ILCA大会上肝癌领域的重磅研究进行汇总，供广大同道学习交流。

 

最新临床研究进展

General Session 4 – Therapy & Miscellaneous & Clinical Trials in Progress

 

阿替利珠单抗加贝伐单抗在常规临床实践中的观察注册研究：AB-Real国际研究的初步结果

O-13 Observational registry of atezolizumab plus bevacizumab use in routine clinical practice: preliminary results of the AB-Real international study.

报告人：Claudia Angela Maria Fulgenzi (UK)

 

ADP-A2AFP靶向T细胞在晚期肝癌或表达甲胎蛋白的其他癌症类型患者中的I期试验的总体安全性和有效性

O-14 Overall safety and efficacy from the Phase 1 trial of ADP-A2AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma or other cancer types expressing alpha-fetoprotein

报告人：Tim Meyer (UK)

 

培美替尼治疗局部晚期经治或转移性胆管癌：FIGHT-202的最终结果

O-27 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202

报告人：Ghassan Abou-Alfa (USA)

 

曲利单抗联合杜鲁单抗治疗不可切除肝细胞癌患者的疗效和不良事件概况：HIMALAYA III期临床试验

O-28 Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab plus Durvalumab in Patients with Unresectable Hepatocellular Carcinoma in the Phase 3 HIMALAYA Trial

报告人：Bruno Sangro (Spain)

 

Young Investigator Session

 

阿替利珠单抗联合贝伐单抗 vs 仑伐替尼或索拉非尼治疗非病毒性不可切除肝细胞癌：一项国际倾向评分匹配分析

O-19 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

报告人：Margherita Rimini (Italy)

 

General Session 2 - Epidemiology, Staging and Prognosis
 

肝细胞癌淋巴结转移局部治疗的疗效

O-01 Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma

报告人：Jinsil Seong (Republic of Korea)

 

欧洲肝癌肝移植进展：来自欧洲肝移植登记处32858例病例分析报告

O-02 Evolution of Liver Transplantation for Hepatocellular Carcinoma in Europe. An Analysis of 32 858 cases from the European Liver Transplant Registry (ELTR)

报告人：Rene Adam (France)

 

诊断与预后研究

General Session 2 - Epidemiology, Staging and Prognosis

 

腹部超声监测亚厘米级肝脏病变的模式变化和肝癌风险

O-03 Variation in surveillance patterns and risk of HCC for sub-centimeter liver lesions on abdominal ultrasound

报告人：Amit Singal (USA)

 

非酒精性脂肪性肝炎（NASH）与非NASH相关性肝癌的肝移植预后比较

O-04 Outcomes of Liver Transplantation in Non-Alcoholic Steatohepatitis (NASH) Versus Non-NASH Associated Hepatocellular Carcinoma

报告人：Luckshi Rajendran (Canada)

 

General Session 3 – Diagnosis, Imaging and Biomarkers

细胞外囊泡表面蛋白检测在肝癌早期诊断中的应用

O-09 An Extracellular Vesicle Surface Protein Assay for Early Detection of Hepatocellular Carcinoma

报告人：Ju Dong Yang (USA)

 

泰国肝细胞癌和肝内胆管癌的肠道微生物群概况

O-26 Landscape of gut microbiome in Thai Hepatocellular Carcinoma and intrahepatic Cholangiocarcinoma

报告人：Yotsawat Pomyen (Thailand)

 

巢蛋白免疫染色对肝细胞-胆管癌的诊断和预后价值

O-21 Diagnostic and prognostic value of Nestin immunostaining in combined Hepatocellular- Cholangiocarcinoma

报告人：Stefano Caruso (France)

 

肝癌蛋白质生物标志物

O-29 Protein biomarkers in HCC

报告人：Robin Zenlander (Sweden)

 

基础与转化研究

 

General Session 1 - Molecular Pathogenesis, Cell Biology and Translational Research

 

CSF1R+PD-L1+肿瘤相关巨噬细胞在肝癌侵袭边缘触发MAIT细胞功能障碍

O-01 CSF1R+PD-L1+ Tumor-associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin

报告人：Benjamin Ruf (USA)

 

HLA II类限制性高亲和力新抗原水平的升高与肝细胞癌患者选择性内放射治疗（SIRT）联合纳武利尤单抗治疗的预后改善相关

O-02 Enhanced levels of HLA class II-restricted high affinity neoantigens are associated with improved outcome to SIRT plus nivolumab in hepatocellular carcinoma

报告人：Belen Aparicio de la Torre (Spain)

 

CD226/CD155在肝癌免疫监测中的作用

O-03 Functional role of the couple CD226/CD155 in the immunosurveillance of Hepatocellular Carcinoma

报告人：Joana Gonc?alves Araujo (France)

 

PMEPA1在TGFβ信号转导的背景下促进肝癌进展

O-04 PMEPA1 promotes hepatocellular carcinoma development in the context of TGFβ signaling

报告人：Roser Pinyol (Spain)

 

敬请期待我们关于ILCA2022后续的精彩报道。

 

声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。